Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Core Insights - Pasithea Therapeutics Corp. is participating in the H.C. Wainwright 27 Annual Global Investment Conference scheduled for September 8-10, 2025, in New York City [1][2] - The CEO, Dr. Tiago Reis Marques, will present the company and is available for one-on-one meetings during the event [2] - Pasithea is focused on developing PAS-004, a next-generation macrocyclic MEK inhibitor, currently in Phase 1 clinical trials for advanced cancer and neurofibromatosis type 1 [2] Company Overview - Pasithea Therapeutics is a clinical-stage biotechnology company dedicated to researching and developing PAS-004 for treating RASopathies, MAPK pathway-driven tumors, and other diseases [2] - PAS-004 is being tested in two clinical trials: a Phase 1 trial for advanced cancer patients (NCT06299839) and a Phase 1/1b trial for adult patients with NF1-associated plexiform neurofibromas (NCT06961565) [2]